PO-1172: dose effects due to interfractional variability for hypofractionated radiotherapy of prostate cancer. (November 2020) - Splinter, M.; Sachpazidis, I.; Bostel, T.; Häring, P.; Lang, C.; Grosu, A.; Debus, J.; Baltas, D.; Nicolay, N.H.